 | Up a level |
Abruzzo, Lynne, Herling, Carmen, Coombes, Kevin, Benner, Axel, Bloehdorn, Johannes, Barron, Lynn L., Abrams, Zachary, Majewski, Tadeusz, Bondaruk, Jolanta, Bahlo, Jasmin, Fischer, Kirsten, Hallek, Michael, Stilgenbauer, Stephan, Czerniak, Bogdan, Oakes, Christopher, Ferrajoli, Alessandra and Keating, Michael (2020). Gene expression signatures predict time-to-progression after front-line chemoimmunotherapy for CLL. Leuk. Lymphoma, 61. S. 7 - 9. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403
Herling, Carmen D., Coombes, Kevin R., Benner, Axel, Bloehdorn, Johannes, Barron, Lynn L., Abrams, Zachary B., Majewski, Tadeusz, Bondaruk, Jolanta E., Bahlo, Jasmin, Fischer, Kirsten, Hallek, Michael, Stilgenbauer, Stephan, Czerniak, Bogdan A., Oakes, Christopher C., Ferrajoli, Alessandra, Keating, Michael J. and Abruzzo, Lynne V. (2019). Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. Lancet Oncol., 20 (11). S. 1576 - 1587. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488